Video
Vibegron shows efficacy among patients with OAB
Author(s):
“This analysis of this publication confirms the link between efficacy and the patient perception, and that the results are actually meaningful to the patients as well,” says Cornelia Haag-Molkenteller, MD. PhD.
In this video, Cornelia Haag-Molkenteller, MD, PhD, discusses the background and findings of the study, “Once-daily vibegron 75 mg for overactive bladder: Long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR).” Haag-Molkenteller is a chief medical officer at Urovant Sciences, Inc in Irvine, California.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Related Content
